Insider · CIK 0001783503

Avagliano Mark

Reports to the SEC for 1 company · RESEARCH TRIANGLE PARK, NC

sec.gov

Transactions

Companies

Filings

CIK

0001783503

Forms 4 and 5

Insider transactions

24 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-09-18	G1 Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Business Officer	DDisposition to Issuer	−41.1K sh	—	—	0
2024-09-18	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+20.6K sh	—	—	262,645
2024-09-18	G1 Therapeutics, Inc.D Disposition to Issuer	Chief Business Officer	DDisposition to Issuer	−237K sh	—	—	26,035
2024-09-18	G1 Therapeutics, Inc.U Disposition from Tender	Chief Business Officer	UDisposition from Tender	−26K sh	—	—	0
2024-09-18	G1 Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Business Officer	DDisposition to Issuer	−89.4K sh	—	—	0
2024-07-05	G1 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−2,638 sh	$2.51	−$6,615.313	242,045
2024-07-01	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+35K sh	—	—	244,683
2024-05-13	G1 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−8,151 sh	$4.79	−$39K	209,683
2024-03-20	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+100K sh	—	—	217,834
2024-01-04	G1 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−721 sh	$2.94	−$2,121.398	117,834
2024-01-03	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+44.8K sh	—	—	121,915
2024-01-03	G1 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−2,602 sh	$3.12	−$8,115.378	118,555
2024-01-03	G1 Therapeutics, Inc.Stock Options (Right to Buy)A Award	Chief Business Officer	AAward	+89.4K sh	—	—	89,400
2024-01-03	G1 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−758 sh	$3.12	−$2,364.126	121,157
2023-05-10	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+35K sh	—	—	77,155
2023-01-03	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+20.6K sh	—	—	42,155
2023-01-03	G1 Therapeutics, Inc.Stock Options (Right to buy)A Award	Chief Business Officer	AAward	+41.1K sh	—	—	41,100
2022-01-05	G1 Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−1,445 sh	$10.61	−$15.3K	21,555
2022-01-03	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+12K sh	—	—	23,000
2022-01-03	G1 Therapeutics, Inc.Stock Options (Right to buy)A Award	Chief Business Officer	AAward	+53K sh	—	—	53,000
2021-01-04	G1 Therapeutics, Inc.A Award	Chief Business Officer	AAward	+11K sh	—	—	11,000
2021-01-04	G1 Therapeutics, Inc.Stock Options (Right to Buy)A Award	Chief Business Officer	AAward	+58K sh	—	—	58,000
2020-02-06	G1 Therapeutics, Inc.Stock Options (Right to Buy)A Award	Chief Business Officer	AAward	+60K sh	—	—	60,000
2019-07-29	G1 Therapeutics, Inc.Stock Option (Right to Buy)A Award	Chief Business Officer	AAward	+300K sh	—	—	300,000

Recent filings

Accepted (ET)
Sep 184
Avagliano Mark0000950170-24-107795
SEC(opens sec.gov)
Jul 84
Avagliano Mark0001562180-24-005657
SEC(opens sec.gov)
Jul 34
Avagliano Mark0001562180-24-005605
SEC(opens sec.gov)
May 154
Avagliano Mark0001562180-24-004057
SEC(opens sec.gov)
Mar 224
Avagliano Mark0001562180-24-002949
SEC(opens sec.gov)
Jan 84
Avagliano Mark0001562180-24-000323
SEC(opens sec.gov)
May 124
Avagliano Mark0001562180-23-004098
SEC(opens sec.gov)
Jan 54
Avagliano Mark0001562180-23-000251
SEC(opens sec.gov)
Jan 54
Avagliano Mark0001562180-22-000303
SEC(opens sec.gov)

Companies

G1 Therapeutics, Inc.Chief Business Officer

Address

C/O G1 THERAPEUTICS, 79 TW ALEXANDER DR. 4501 RESEARCH COMMONS, SUITE 100

RESEARCH TRIANGLE PARK, NC, 27709